We wanted to reach out as soon as possible to alert you that today we announced that the FDA will not be approving Phathom’s NDA for vonoprazan for treatment of erosive esophagitis (EE) on the January 11, 2023, PDUFA target action date as we originally expected. Based on this recent development, we no longer be launching vonoprazan for treatment EE or H. pylori infection in the first quarter of 2023. Regrettably, this development means that we will not be extending you a formal offer to join Phathom as a sales representative at this time.
We sincerely appreciate your interest and willingness to join Phathom and share your disappointment. We wish you all the best in your future endeavors and will remain in touch as we work with FDA to bring our products to patients.